PUBBLICATO IL NUOVO NUMERO DELLA WHO PHARMACEUTICAL NEWSLETTER

Fonte: WHO. N 6, dicembre 2017

E' disponibile il nuovo numero della WHO Pharmaceutical newsletter.

In questo numero:

REGULATORY MATTERS
• Amoxicillin containing products
• Chlorhexidine containing products
• Clozapine
• Codeine-containing products
• Daclizumab
• DPP-4 inhibitors
• Fingolimod
• Fluconazole
• Fluconazole (non-prescription)
• Green tea extract-containing natural health products
• Ibrutinib
• Levetiracetam
• Linagliptin
• Moxifloxacin (oral dosage form)
• Terbinafine

SAFETY OF MEDICINE
• Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)
Chlorhexidine
• Clozapine
• Febuxostat
• Finasteride
• Flupirtine-containing medicines
• Gabapentin
• Hydroxyethyl-starch containing medicines
• Intraocular injections of a compounded triamcinolone, moxifloxacin and vancomycin (TMV) formulation
• Isotretinoin

SIGNAL
• Natalizumab and rapidly evolving central nervous system lymphoma

FEATURE
• The 40th Annual Meeting of Representatives of the National Pharmacovigilance Centres participating in the WHO Programme for International Drug Monitoring
• Introducing the WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services